<DOC>
	<DOC>NCT01599637</DOC>
	<brief_summary>The study is designed to explore the mode of action for omalizumab therapy in patients with chronic idiopathic urticaria.</brief_summary>
	<brief_title>Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Diagnosis of chronic spontaneous urticaria refractory to H1 antihistamines at Baseline Clearly defined underlying etiology for chronic urticarias other than CIU (main manifestation being physical urticaria). This includes the following urticarias: Acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact, as well as the following diseases as these diseases may have symptoms of urticaria or angioedema: Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia, or generalized cancer. Previous treatment with omalizumab. A history or presence of atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or other skin disease associated with itch. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Chronic idiopathic urticaria</keyword>
	<keyword>CIU</keyword>
	<keyword>Xolair</keyword>
	<keyword>IGE025</keyword>
	<keyword>FcÎµRI</keyword>
	<keyword>IgE</keyword>
</DOC>